tiprankstipranks
Trending News
More News >
Apiam Animal Health Ltd. (AU:AHX)
ASX:AHX
Australian Market
Advertisement

Apiam Animal Health Ltd. (AHX) AI Stock Analysis

Compare
6 Followers

Top Page

AU:AHX

Apiam Animal Health Ltd.

(Sydney:AHX)

Rating:57Neutral
Price Target:
AU$0.50
▼(-10.71%Downside)
Apiam Animal Health Ltd. has a strong financial performance with robust revenue growth and cash flow management, which significantly supports its stock score. However, technical indicators highlight potential short-term risks due to overbought conditions, and the stock appears overvalued based on its high P/E ratio. These factors collectively result in a moderate overall stock score.

Apiam Animal Health Ltd. (AHX) vs. iShares MSCI Australia ETF (EWA)

Apiam Animal Health Ltd. Business Overview & Revenue Model

Company DescriptionApiam Animal Health Limited, a vertically integrated animal health company, provides veterinary products and services to production and companion animals in Australia. The company operates through three segments: Dairy and Mixed, Feedlots, and Pigs. It engages in the provision of veterinary wholesale, diagnostics laboratories, custom vaccines, logistics, and other ancillary services. The company offers companion animal, dairy, swine and poultry, beef feedlot, equine, sheep, and genetic services. It also provides telemedicine, remote video headgear, health management apps for production animals systems, benchmarking databases, and herd management software. The company offers general animal health products through eCommerce. It provides its services through animal veterinary clinics. The company was founded in 1998 and is based in Bendigo, Australia.
How the Company Makes MoneyApiam Animal Health Ltd. generates revenue through multiple streams, including fees for veterinary services, sales of animal health products, and diagnostic services. The company operates a network of veterinary clinics and hospitals that provide services to both livestock producers and pet owners. Additionally, Apiam benefits from significant partnerships with pharmaceutical companies and suppliers, which enable them to offer a diverse range of products. The company's earnings are bolstered by its focus on preventative health solutions, which drive recurring revenue through regular health check-ups and ongoing treatment programs.

Apiam Animal Health Ltd. Financial Statement Overview

Summary
Apiam Animal Health Ltd. presents a strong financial performance with significant revenue growth and improving operational efficiencies. While profitability margins show room for improvement, the company’s robust cash flow management and balanced debt levels provide a solid foundation for future growth.
Income Statement
75
Positive
Apiam Animal Health Ltd. has shown a strong revenue growth trajectory with a significant increase from previous years, indicating robust business expansion. The Gross Profit Margin has improved substantially, reflecting effective cost management. However, the Net Profit Margin remains relatively low, suggesting room for improvement in overall profitability. The EBIT and EBITDA margins have shown positive trends, enhancing operational efficiency.
Balance Sheet
70
Positive
The company maintains a moderate Debt-to-Equity Ratio, indicating a balanced approach to leveraging. Return on Equity (ROE) reflects a moderate level of profitability relative to shareholder investments. The Equity Ratio is stable, suggesting a sound capital structure. However, the total debt level has increased, which could pose future financial risks if not managed properly.
Cash Flow
80
Positive
Apiam Animal Health Ltd. demonstrates a healthy Cash Flow position with consistent Free Cash Flow generation and positive Operating Cash Flow growth. The Free Cash Flow to Net Income ratio indicates efficient cash management, supporting potential reinvestment opportunities. The Operating Cash Flow to Net Income Ratio signifies strong cash generation capabilities from core operations.
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue204.66M191.76M157.06M126.18M118.33M
Gross Profit137.16M28.81M25.98M20.57M19.26M
EBITDA23.52M17.11M16.31M14.64M13.72M
Net Income4.93M2.28M4.64M5.08M4.17M
Balance Sheet
Total Assets255.78M246.04M199.18M157.28M141.67M
Cash, Cash Equivalents and Short-Term Investments1.76M3.17M2.85M2.15M2.51M
Total Debt101.78M98.03M63.39M55.04M51.10M
Total Liabilities133.75M128.14M90.49M76.46M73.23M
Stockholders Equity122.02M117.87M108.55M79.81M67.41M
Cash Flow
Free Cash Flow14.01M9.25M10.21M8.71M5.52M
Operating Cash Flow18.88M17.45M15.08M13.69M7.51M
Investing Cash Flow-10.91M-40.62M-32.49M-16.56M-14.86M
Financing Cash Flow-9.39M23.49M18.11M2.51M7.99M

Apiam Animal Health Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.56
Price Trends
50DMA
0.49
Positive
100DMA
0.44
Positive
200DMA
0.43
Positive
Market Momentum
MACD
0.02
Positive
RSI
54.79
Neutral
STOCH
38.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:AHX, the sentiment is Positive. The current price of 0.56 is below the 20-day moving average (MA) of 0.56, above the 50-day MA of 0.49, and above the 200-day MA of 0.43, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 54.79 is Neutral, neither overbought nor oversold. The STOCH value of 38.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:AHX.

Apiam Animal Health Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
AU$94.51M34.722.10%11.24%
66
Neutral
AU$26.78M98.610.37%1.41%13.92%
63
Neutral
AU$113.75M28.031.60%7.91%-10.06%
62
Neutral
AU$627.78M28.987.01%3.21%17.98%8.65%
62
Neutral
$16.45B10.04-7.39%3.35%1.53%-21.72%
57
Neutral
AU$103.01M700.000.11%3.57%2.00%-94.63%
€5.86M
* Consumer Cyclical Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:AHX
Apiam Animal Health Ltd.
0.56
0.20
55.56%
DE:N1R
AF Legal Group Limited
0.22
0.00
0.00%
AU:PFP
Propel Funeral Partners Ltd.
4.55
-1.04
-18.60%
AU:SHJ
Shine Justice Ltd.
0.67
0.02
3.08%
AU:EXP
Experience Co Ltd
0.12
-0.02
-14.29%
AU:MFD
Mayfield Childcare Ltd.
0.36
-0.29
-44.62%

Apiam Animal Health Ltd. Corporate Events

Apiam Animal Health Appoints Bruce Dixon as Interim Managing Director
Jul 31, 2025

Apiam Animal Health Limited has appointed Mr. Bruce Dixon as the Interim Managing Director, effective August 1, 2025. The agreement for his services includes a weekly remuneration of $7,750 and can be terminated with one week’s notice. This leadership change is expected to influence the company’s operations and strategic direction.

The most recent analyst rating on (AU:AHX) stock is a Buy with a A$0.63 price target. To see the full list of analyst forecasts on Apiam Animal Health Ltd. stock, see the AU:AHX Stock Forecast page.

Apiam Animal Health Corrects Director’s Share Purchase Report
Jul 4, 2025

Apiam Animal Health Limited announced a correction to a previously lodged Appendix 3Y regarding the number of shares purchased by Director Ms. Vita Pepe. The initial report overstated the shares acquired, which were corrected from 105,597 to 78,625 shares. This administrative correction ensures accurate reporting of director interests, reflecting the company’s commitment to transparency and compliance with regulatory requirements.

The most recent analyst rating on (AU:AHX) stock is a Buy with a A$0.63 price target. To see the full list of analyst forecasts on Apiam Animal Health Ltd. stock, see the AU:AHX Stock Forecast page.

Apiam Animal Health Director Increases Shareholding
Jun 25, 2025

Apiam Animal Health Ltd. announced a change in the shareholding of its director, Vita Pepe, who acquired 105,957 fully paid ordinary shares through on-market trades. This transaction increases Pepe’s total shareholding to 13,101,455 shares, reflecting confidence in the company’s market position and potential growth, which may positively impact stakeholder perceptions.

The most recent analyst rating on (AU:AHX) stock is a Buy with a A$0.63 price target. To see the full list of analyst forecasts on Apiam Animal Health Ltd. stock, see the AU:AHX Stock Forecast page.

Apiam Animal Health Ltd. Director Increases Shareholding
Jun 17, 2025

Apiam Animal Health Ltd. has announced a change in the director’s interest, with Director Vita Pepe acquiring 68,238 fully paid ordinary shares through on-market trades. This change reflects a slight increase in the director’s stake in the company, potentially signaling confidence in the company’s future prospects.

The most recent analyst rating on (AU:AHX) stock is a Buy with a A$0.63 price target. To see the full list of analyst forecasts on Apiam Animal Health Ltd. stock, see the AU:AHX Stock Forecast page.

Apiam Animal Health Appoints Vita Pepe as Non-Executive Director
Jun 13, 2025

Apiam Animal Health Limited has appointed Ms. Vita Pepe as a Non-Executive Director to its board, effective immediately. Ms. Pepe brings extensive experience in value creation across various sectors, including healthcare and commercial services, and her appointment aligns with Apiam’s strategy to enhance productivity and operational efficiency. Her expertise is expected to support Apiam’s growth and profitability goals, further strengthening the board’s capabilities in achieving long-term objectives.

The most recent analyst rating on (AU:AHX) stock is a Buy with a A$0.63 price target. To see the full list of analyst forecasts on Apiam Animal Health Ltd. stock, see the AU:AHX Stock Forecast page.

Apiam Animal Health Announces Leadership Transition with Interim CEO Appointment
Jun 5, 2025

Apiam Animal Health Limited has announced a leadership transition with the departure of Dr. Chris Richards as CEO and Managing Director after over nine years. Bruce Dixon, a non-executive director with a proven track record in profitable growth, will serve as Interim Managing Director while the company searches for a new CEO. The transition aims to maintain focus on revenue opportunities and operational efficiencies within Apiam’s clinic portfolio, signaling a strategic shift in leadership to support continued growth and development.

The most recent analyst rating on (AU:AHX) stock is a Buy with a A$0.63 price target. To see the full list of analyst forecasts on Apiam Animal Health Ltd. stock, see the AU:AHX Stock Forecast page.

Apiam Animal Health Reports Resilient FY25 Results and Launches AI Tool
May 5, 2025

Apiam Animal Health Ltd. reported resilient financial results for the fiscal year 2025 to date, despite challenges in the equine market and reduced export diagnostic testing revenues. The company has divested two underperforming clinics to improve EBIT and is rolling out CoVet, an AI-driven clinical tool, to enhance efficiency and customer experience across its network. This strategic move is expected to streamline workflows, increase clinic capacity, and improve both employee and customer satisfaction, positioning Apiam favorably in the veterinary services industry.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 10, 2025